# Trump announces all 50 states join Medicaid drug pricing deal

> The administration claims billions in savings from a new program linking U.S. drug prices to other wealthy nations, but details remain secret.
- Title: Trump announces all 50 states join Medicaid drug pricing deal
- Summary: The administration claims billions in savings from a new program linking U.S. drug prices to other wealthy nations, but details remain secret. Trump's most…
- Keywords: trump administration, medicaid, drug pricing, most favored nation policy, pharmaceutical companies, prescription drug costs, healthcare affordability, state budgets, cost of living, midterm elections, news, Trump
- Source: ABC News — https://abcnews.com/Business/wireStory/trump-announce-50-states-joining-medicaid-drug-pricing-136568113
- Author: ABC News
- Read time: 1 min
- Topics: trump administration, medicaid, drug pricing, most favored nation policy, pharmaceutical companies, prescription drug costs, healthcare affordability, state budgets, cost of living, midterm elections, news
## Trump announces nationwide Medicaid drug deal
President Trump will announce Friday that all 50 states are joining the Medicaid GENEROUS model, which ties U.S. drug prices to the lowest prices paid in other wealthy countries.
## White House projects $529 billion savings
The Trump administration estimates the program will save $529 billion over the next 10 years by negotiating lower prescription drug prices with pharmaceutical companies.
## Secret deals block independent verification
Few details of the agreements between the Trump administration and pharmaceutical companies have been made public, making it impossible for experts to independently verify the claimed savings.

> No one knows what is in these deals.
## Policy experts demand more transparency
Kathy Hempstead from the Robert Wood Johnson Foundation says Congress needs granular data to justify the cost-savings claims and to consider codifying the pricing arrangements into law.

> He is saying Congress should codify all of his MFN arrangements. But it's kind of unreasonable because it's not clear what Congress would actually do.
## Concerns about program longevity
Experts worry that price cuts may not survive beyond the Trump administration, potentially reverting to higher levels once the current administration leaves office.
## Progress incomplete for uninsured Americans
Pharmaceutical reform advocates say the announcement shows progress but millions of Americans without government healthcare coverage still lack access to lower drug prices.

> meaningful progress, but that progress remains incomplete
## Key takeaway

Trump's most favored nation pricing model expands to all states, though independent verification of promised savings is impossible without public deal details.